| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
19,740,000 |
| Market
Cap: |
4.53(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,297,425 |
| 52
Week Range: |
$120.4 - $284.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 21.9 |
| Insider 3/6 Months : 22.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
136,370 |
424,685 |
424,685 |
| Total Buy Value |
$0 |
$30,065,193 |
$77,751,391 |
$77,751,391 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
3 |
10 |
10 |
| Total Shares Sold |
276,067 |
293,667 |
293,667 |
363,156 |
| Total Sell Value |
$67,426,178 |
$71,246,652 |
$71,246,652 |
$90,715,080 |
| Total People Sold |
7 |
8 |
8 |
9 |
| Total Sell Transactions |
15 |
23 |
23 |
28 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ehrlich Keith S |
VP, Fin. and Admin., CFO |
• – – |
2010-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,284 |
20,110 |
|
- |
|
| Vukovic Vojo |
SVP, Chief Medical Officer |
• – – |
2010-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,477 |
14,107 |
|
- |
|
| Koya Keizo |
Sr. VP, Drug Development |
• – – |
2010-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,224 |
51,269 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2010-01-08 |
4 |
B |
$4.50 |
$2,475,000 |
D/D |
550,000 |
1,500,673 |
3.92 |
- |
|
| Gollust Keith R |
Director |
– • – |
2010-01-08 |
4 |
B |
$4.50 |
$450,000 |
D/D |
100,000 |
164,079 |
2.39 |
- |
|
| Wilson Robert N |
Director |
– • – |
2010-01-08 |
4 |
B |
$4.50 |
$450,000 |
D/D |
100,000 |
464,677 |
2.39 |
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2010-01-08 |
4 |
B |
$4.50 |
$99,999 |
D/D |
22,222 |
2,292,747 |
2.81 |
- |
|
| Chen Lan Bo |
Director |
– • • |
2009-11-20 |
5 |
GA |
$0.00 |
$0 |
I/I |
13,200 |
15,160 |
|
- |
|
| Chen Lan Bo |
Director |
– • • |
2009-11-20 |
5 |
GD |
$0.00 |
$0 |
I/I |
46,200 |
824,195 |
|
- |
|
| Chen Lin Huey |
10% Owner |
– – • |
2009-11-20 |
5 |
GA |
$0.00 |
$0 |
I/I |
13,200 |
15,160 |
|
- |
|
| Chen Lin Huey |
10% Owner |
– – • |
2009-11-20 |
5 |
GD |
$0.00 |
$0 |
I/I |
46,200 |
824,195 |
|
- |
|
| Koya Keizo |
Sr. VP, Drug Development |
• – – |
2009-08-24 |
4 |
B |
$2.84 |
$28,434 |
D/D |
10,000 |
43,045 |
2.74 |
- |
|
| Chen Lin Huey |
10% Owner |
– – • |
2009-08-06 |
4 |
B |
$2.88 |
$57,600 |
I/I |
20,000 |
620,035 |
1.5 |
- |
|
| Chen Lan Bo |
Director |
– • • |
2009-08-06 |
4 |
B |
$2.88 |
$57,600 |
D/D |
20,000 |
620,035 |
3.92 |
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2009-08-06 |
4 |
B |
$2.78 |
$57,009 |
D/D |
20,000 |
2,270,525 |
2.81 |
- |
|
| Vukovic Vojo |
SVP, Chief Medical OfficerOffi |
• – – |
2009-07-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,630 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2009-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,806 |
950,673 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2009-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,806 |
64,079 |
|
- |
|
| Wilson Robert N |
Director |
– • – |
2009-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,403 |
364,677 |
|
- |
|
| Chadwick Jeremy G |
Sr. VP, Pgm Mgmt and Clin Ops |
• – – |
2009-01-05 |
4 |
AS |
$6.20 |
$28,375 |
D/D |
(4,573) |
15,853 |
|
- |
|
| Ehrlich Keith S |
VP, Fin. and Admin., CFO |
• – – |
2009-01-05 |
4 |
AS |
$6.18 |
$34,619 |
D/D |
(5,600) |
14,826 |
|
- |
|
| Rieder Wendy E |
VP, IP and Legal, Gen. Counsel |
• – – |
2009-01-05 |
4 |
AS |
$6.18 |
$30,888 |
D/D |
(5,000) |
15,426 |
|
- |
|
| Chen Lan Bo |
Director |
– • • |
2008-09-11 |
5 |
GA |
$0.00 |
$0 |
I/I |
5,000 |
8,560 |
|
- |
|
| Chen Lan Bo |
Director |
– • • |
2008-09-11 |
5 |
GD |
$0.00 |
$0 |
D/D |
17,500 |
600,035 |
|
- |
|
| Chen Lin Huey |
10% Owner |
– – • |
2008-09-11 |
5 |
GA |
$0.00 |
$0 |
I/I |
5,000 |
8,560 |
|
- |
|
416 Records found
|
|
Page 14 of 17 |
|
|
5.27 (2.24%) 
